scholarly journals Clinical characteristics of cancer of unknown primary cancer with poorly differentiated carcinoma and adenocarcinoma

2015 ◽  
Vol 26 ◽  
pp. vii86
Author(s):  
Makoto Kodaira ◽  
Tatsunori Shimoi ◽  
Jun Hashimoto ◽  
Harukaze Yamamoto ◽  
Mayu Yunokawa ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Cancer Of Unknown Primary ◽  
Unknown Primary ◽  
Primary Cancer ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated

scholarly journals Pineal Gland Metastasis From Poorly Differentiated Carcinoma of Unknown Primary Origin

2020 ◽  
Vol 11 ◽  
Author(s):  
Joshua A. Cuoco ◽  
Michael W. Kortz ◽  
Michael J. Benko ◽  
Robert W. Jarrett ◽  
Cara M. Rogers ◽  
...  
Keyword(s):  
Pineal Gland ◽  
Unknown Primary ◽  
Carcinoma Of Unknown Primary ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Primary Origin ◽  
Unknown Primary Origin

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

1997 ◽  
Vol 15 (5) ◽  
pp. 2056-2066 ◽  
Author(s):  
R Lenzi ◽  
K R Hess ◽  
M C Abbruzzese ◽  
M N Raber ◽  
N G Ordoñez ◽  
...  
Keyword(s):  
Median Survival ◽  
Proportional Hazards ◽  
Primary Carcinoma ◽  
Unknown Primary ◽  
Entire Group ◽  
Poorly Differentiated Adenocarcinoma ◽  
Prognostic Features ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Unknown Primary Carcinoma

PURPOSE The objectives of this study were to assess clinical outcomes and prognostic factors in unselected, consecutive patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA). PATIENTS AND METHODS The 1,400 patients analyzed were referred to our unknown-primary tumor (UPT) clinic from January 1, 1987 through July 31, 1994. Clinical data from these patients were entered into a computerized data base for storage, retrieval, and analysis. Survival was measured from the time of diagnosis; survival distribution was estimated using the product-limit method. Multivariate survival analyses were performed using proportional hazards regression and by recursive partitioning. RESULTS Nine hundred seventy-seven patients were diagnosed with unknown-primary carcinoma (UPC) and 337 of these patients had PDC or PDA. No clinical differences were identified among patients with PDC, PDA, or UPC patients with other carcinoma or adenocarcinoma subtypes. PDC patients enjoyed better survival than PDA patients. Poor cellular differentiation was not an important prognostic variable. Variables predictive of survival included lymph node metastases, sex, number of metastatic sites, histology (PDC v PDA), and age. Although chemotherapy did not appear to influence survival for the entire group of PDC or PDA patients, a subset of patients with good prognostic features experienced median survival durations of up to 40 months. CONCLUSION The long median survival and chemotherapy responsiveness of UPC patients with PDC and PDA could not be confirmed. However, subpopulations with prolonged median survival durations could be defined, and the value of chemotherapy in this group remains to be determined. Identification and exclusion of treatable or slow-growing malignancies may account for the poor survival of the PDC and PDA patients reported in this study.

Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.

1991 ◽  
Vol 9 (11) ◽  
pp. 1931-1938 ◽  
Author(s):  
J D Hainsworth ◽  
E P Wright ◽  
D H Johnson ◽  
B W Davis ◽  
F A Greco
Keyword(s):  
Yolk Sac ◽  
Primary Site ◽  
Unknown Primary ◽  
Immunoperoxidase Staining ◽  
Unknown Primary Site ◽  
Carcinoma Of Unknown Primary ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
Long Term Survivors

To assess the clinical utility of immunoperoxidase tumor-cell staining in patients with poorly differentiated carcinoma of unknown primary site, we performed a battery of stains on tumors from 87 patients treated between August 1978 and April 1983. Poorly differentiated carcinoma or poorly differentiated adenocarcinoma was diagnosed on the basis of light microscopic examination, and all patients were treated before the technology of immunoperoxidase staining was routinely used. Therefore, results of immunoperoxidase staining can be correlated with clinical outcome in this group of similarly treated patients with a long median follow-up. Immunoperoxidase staining confirmed the diagnosis of poorly differentiated carcinoma in 49 patients (56%) and yielded other diagnoses in 14 patients (16%): melanoma, eight; lymphoma, four; prostatic carcinoma, one; and yolk sac carcinoma, one. In 24 patients (28%) the immunoperoxidase staining pattern was inconclusive; electron microscopy was usually helpful in clarifying the diagnosis in these patients. Seventy-five patients (86%) received combination chemotherapy with a cisplatin-based regimen, and 24 patients (28%) had a complete response. Nine of these patients were later given specific diagnoses by immunoperoxidase staining (lymphoma, four; melanoma, four; yolk sac tumor, one). All patients with an immunoperoxidase diagnosis of lymphoma also had clinical features compatible with lymphoma and are long-term survivors. Patients with immunoperoxidase features suggesting melanoma were surprisingly responsive to chemotherapy, with three of seven complete responses and two long-term survivors. Patients with melanoma diagnosed by immunoperoxidase staining should not be excluded from a trial of cisplatin-based therapy. Immunoperoxidase staining is useful in the routine evaluation of metastatic poorly differentiated carcinoma of unknown primary site, as it can occasionally suggest the lineage of the tumor and have specific therapeutic implications.

scholarly journals Clinical characteristics of cancer of unknown primary site based on a new risk category

2016 ◽  
Vol 27 ◽  
pp. vii83
Author(s):  
Makoto Kodaira ◽  
Tatsunori Shimoi ◽  
Kan Yonemori ◽  
Akihiko Shimomura ◽  
Mayu Yunokawa ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Risk Category ◽  
Unknown Primary Site

scholarly journals Axillary Lymph Nodal Metastasis from Carcinoma of Unknown Primary (CUPAx)- An Orphan Disease

2021 ◽  
Author(s):  
Renuka Bangalore Nagaraj ◽  
MD Khursid Alam Ansari
Keyword(s):  
Lymph Node ◽  
Primary Tumour ◽  
Nodal Metastasis ◽  
Unknown Primary ◽  
Axillary Lymph ◽  
Poorly Differentiated Carcinoma ◽  
Ultrasound Sonography ◽  
Metastatic Nodule ◽  
Poorly Differentiated

Metastasis to axillary lymph node occurs in adenocarcinoma or poorly differentiated carcinoma, and is a rare clinical entity that needs to be understood for management and its clinical outcome. The present case is of 72-year-old female patient who had a metastatic nodule in the axilla. No breast mass was palpable. Histology identified as metastatic adenocarcinoma, however mammography and Ultrasound Sonography test (USg) failed to detect the primary tumour. Immunohistochemistry showed that the excised lymph node was positive for Estrogen Receptor (ER) and negative for Progesterone Receptor (PR), suggesting the breast as the site for the primary tumour. Since the patient refused surgery, she was under follow-up for eight months. Now, she presented with recurrence of similar axillary swelling for two months.

scholarly journals Management of cancer of unknown primary

2020 ◽  
Vol 48 (2-3) ◽  
pp. 85-88
Author(s):  
Iva Andrašek ◽  
◽  
Mirna Ravlić ◽  
Martina Mikulandra ◽  
Franjo Cmrečak ◽  
...  
Keyword(s):  
Metastatic Tumor ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Combined Modality Treatment ◽  
Tumor Type ◽  
Patients With Cancer ◽  
Poorly Differentiated ◽  
Primary Origin ◽  
Chemotherapy Agents

Cancer of an unknown primary site is most commonly an aggressive metastatic tumor with a median patient survival of 6 to 9 months. Histologically, it is predominantly adenocarcinoma, and if the primary site is subsequently diagnosed, it is usually the pancreas or lung. Biopsy should be performed whenever possible to classify a tumor of unknown primary origin into one of the following entities: adenocarcinoma, poorly differentiated carcinoma with characteristics similar to adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, poorly differentiated neoplasm. After determining the primary tumor type, the subtype is determined by immunohistochemical staining. In oligometastatic disease, there is a possibility of surgical treatment. Radiotherapy is used as a part of combined modality treatment. Most patients with cancer of unknown primary have an unfavorable prognosis despite multiple chemotherapy agents, and no protocol can be recommended as standard therapy.

Sign in / Sign up

Export Citation Format

Share Document